This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2013
  • /
  • 06
  • /
  • CHMP recommends Pomalidomide Celgene as a treatmen...
Drug news

CHMP recommends Pomalidomide Celgene as a treatment for Multiple Myeloma

Read time: 1 mins
Last updated:1st Jun 2013
Published:1st Jun 2013
Source: Pharmawand

Celgene International S�rl, a wholly-owned subsidiary of Celgene Corporation has announced that the European Medicines Agency�s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Pomalidomide Celgene in combination with dexamethasone for the treatment of relapsed and refractory Multiple Myeloma (rrMM) in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.